Option Care Health reached a fresh 52-week peak following Morgan Stanley’s decision to raise its price target from $35.00 to $38.00 and affirm an overweight rating. Trading volume surged to 2.55 million shares, well above the three-month daily average of 1.9 million, illustrating heightened investor interest. Deutsche Bank also boosted its objective from $31.00 to $36.00 with a buy rating, while Wall Street Zen upgraded to a buy on January 10. The consensus among 14 analysts on MarketBeat is a Moderate Buy, with an average target of $37.17, suggesting further upside potential as market sentiment consolidates around positive third-party validation.

Option Care Health reported preliminary fourth-quarter net revenues of $1.46–1.47 billion, up approximately 8% year-over-year from $1.35 billion. Non-GAAP net income is projected at $73.8–79.0 million, or $0.46–0.49 per share, broadly in line with the prior year’s $75.5 million. Management raised full-year FY2025 EPS guidance to a range of $1.72–1.76 versus a consensus of $1.64, and reiterated FY2026 revenue guidance of $5.8–6.0 billion, slightly below the $6.1 billion street estimate. The stronger profitability outlook and revenue beats validate the company’s strategic investments in specialty infusion therapies and are expected to underpin improved operating leverage in the year ahead.

Director Harry M. Jansen Kraemer, Jr. increased his holding by 38,000 shares at an average cost of $25.98 per share, elevating his total stake to 413,390 shares, a 10.1% increase valued at approximately $10.74 million. Institutional ownership stands at 98.05%, with recent new stakes by USA Financial Formulas ($26,000) and Advisory Services Network LLC ($35,000). Cornerstone Planning Group LLC expanded its position by 7,621%, acquiring 1,067 additional shares for $30,000, signaling confidence in long-term growth prospects. These strategic purchases by insiders and institutions reinforce management’s outlook and demonstrate conviction in the company’s path to sustained margin expansion.